tetano
Editor, Senior Moderator
Vaccine
. 2024 Jun 3:S0264-410X(24)00624-8.
doi: 10.1016/j.vaccine.2024.05.056. Online ahead of print. A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models
Jin Feng[SUP] 1 [/SUP], Yingying Du[SUP] 2 [/SUP], Liyun Chen[SUP] 3 [/SUP], Wenhan Su[SUP] 3 [/SUP], Hailiu Wei[SUP] 3 [/SUP], Aijiao Liu[SUP] 3 [/SUP], Xiaojun Jiang[SUP] 3 [/SUP], Jianmin Guo[SUP] 4 [/SUP], Cailing Dai[SUP] 4 [/SUP], Yuhua Xu[SUP] 5 [/SUP], Tao Peng[SUP] 6 [/SUP]
Affiliations
Globally, influenza poses a substantial threat to public health, serving as a major contributor to both morbidity and mortality. The current vaccines for seasonal influenza are not optimal. A novel recombinant hemagglutinin (rHA) protein-based quadrivalent seasonal influenza vaccine, SCVC101, has been developed. SCVC101-S contains standard dose protein (15μg of rHA per virus strain) and an oil-in-water adjuvant, CD-A, which enhances the immunogenicity and cross-protection of the vaccine. Preclinical studies in mice, rats, and rhesus macaques demonstrate that SCVC101-S induces robust humoral and cellular immune responses, surpassing those induced by commercially available vaccines. Notably, a single injection with SCVC101-S can induce a strong immune response in macaques, suggesting the potential for a standard-dose vaccination with a recombinant protein influenza vaccine. Furthermore, SCVC101-S induces cross-protection immune responses against heterologous viral strains, indicating broader protection than current vaccines. In conclusion, SCVC101-S has demonstrated safety and efficacy in preclinical settings and warrants further investigation in human clinical trials. Its potential as a valuable addition to the vaccines against seasonal influenza, particularly for the elderly population, is promising.
Keywords: Adjuvant; Cross-protection; Elderly; Immunogenicity; Influenza vaccine; Recombinant HA.
. 2024 Jun 3:S0264-410X(24)00624-8.
doi: 10.1016/j.vaccine.2024.05.056. Online ahead of print. A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models
Jin Feng[SUP] 1 [/SUP], Yingying Du[SUP] 2 [/SUP], Liyun Chen[SUP] 3 [/SUP], Wenhan Su[SUP] 3 [/SUP], Hailiu Wei[SUP] 3 [/SUP], Aijiao Liu[SUP] 3 [/SUP], Xiaojun Jiang[SUP] 3 [/SUP], Jianmin Guo[SUP] 4 [/SUP], Cailing Dai[SUP] 4 [/SUP], Yuhua Xu[SUP] 5 [/SUP], Tao Peng[SUP] 6 [/SUP]
Affiliations
- PMID: 38834431
- DOI: 10.1016/j.vaccine.2024.05.056
Globally, influenza poses a substantial threat to public health, serving as a major contributor to both morbidity and mortality. The current vaccines for seasonal influenza are not optimal. A novel recombinant hemagglutinin (rHA) protein-based quadrivalent seasonal influenza vaccine, SCVC101, has been developed. SCVC101-S contains standard dose protein (15μg of rHA per virus strain) and an oil-in-water adjuvant, CD-A, which enhances the immunogenicity and cross-protection of the vaccine. Preclinical studies in mice, rats, and rhesus macaques demonstrate that SCVC101-S induces robust humoral and cellular immune responses, surpassing those induced by commercially available vaccines. Notably, a single injection with SCVC101-S can induce a strong immune response in macaques, suggesting the potential for a standard-dose vaccination with a recombinant protein influenza vaccine. Furthermore, SCVC101-S induces cross-protection immune responses against heterologous viral strains, indicating broader protection than current vaccines. In conclusion, SCVC101-S has demonstrated safety and efficacy in preclinical settings and warrants further investigation in human clinical trials. Its potential as a valuable addition to the vaccines against seasonal influenza, particularly for the elderly population, is promising.
Keywords: Adjuvant; Cross-protection; Elderly; Immunogenicity; Influenza vaccine; Recombinant HA.